GlaxoSmithKline’s advanced Parkinson’s disease drug IPX066 has impressed in a head to head trial against it nearest rival. The phase …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

